A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application
Noah Becher,1 Arun Swaminath,2 Keith Sultan3 1Department of Medicine, Hofstra/Northwell Health at Staten Island University Hospital, Staten Island, NY, USA; 2Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA; 3Division o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-09-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-literature-review-of-ozanimod-therapy-in-inflammatory-bowel-disease--peer-reviewed-fulltext-article-TCRM |
| _version_ | 1811209567031263232 |
|---|---|
| author | Becher N Swaminath A Sultan K |
| author_facet | Becher N Swaminath A Sultan K |
| author_sort | Becher N |
| collection | DOAJ |
| description | Noah Becher,1 Arun Swaminath,2 Keith Sultan3 1Department of Medicine, Hofstra/Northwell Health at Staten Island University Hospital, Staten Island, NY, USA; 2Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA; 3Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USACorrespondence: Keith Sultan, Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 600 Northern Blvd Suite 111, Great Neck, New York, NY, 11021, USA, Tel +1 516-387-3990, Fax +1 516-387-3930, Email ksultan@northwell.eduAbstract: Inflammatory bowel disease (IBD), namely Ulcerative Colitis (UC) and Crohn’s Disease (CD), is believed to be due to a dysregulation of the innate immune response. The complexity of the immune cascade offers both a challenge and an opportunity to researchers seeking out new treatments for IBD, as various points along the inflammatory pathways can be targeted for interruption. Sphinogosine-1-phosphate (S1P) is a phospholipid molecule with wide ranging biological effects caused by binding five known S1P receptor subtypes. Ozanimod is a small molecule drug that selectively targets S1P receptors 1 and 5 which play a crucial role in lymphocyte trafficking. In clinical trials for both UC and CD, it has been shown to induce a reversible lymphopenia which correlates with response to therapy. Reported adverse events include infection, anemia, and elevated liver enzymes. Rare instances of bradycardia, heart block, and macular edema were also reported. As a newly available therapy approved for UC patients, we aim to summarize ozanimod’s novel mechanism of action, pre-clinical and clinical trial results, and to give context to this newly available drug that gastroenterologists may utilize in their treatment algorithm.Keywords: S1P modulator, ozanimod, inflammatory bowel disease, ulcerative colitis, IBD |
| first_indexed | 2024-04-12T04:41:44Z |
| format | Article |
| id | doaj.art-dd3774146b9a4edd804dd4b5eac4b5f1 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-04-12T04:41:44Z |
| publishDate | 2022-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-dd3774146b9a4edd804dd4b5eac4b5f12022-12-22T03:47:38ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2022-09-01Volume 1891392778061A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical ApplicationBecher NSwaminath ASultan KNoah Becher,1 Arun Swaminath,2 Keith Sultan3 1Department of Medicine, Hofstra/Northwell Health at Staten Island University Hospital, Staten Island, NY, USA; 2Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA; 3Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USACorrespondence: Keith Sultan, Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 600 Northern Blvd Suite 111, Great Neck, New York, NY, 11021, USA, Tel +1 516-387-3990, Fax +1 516-387-3930, Email ksultan@northwell.eduAbstract: Inflammatory bowel disease (IBD), namely Ulcerative Colitis (UC) and Crohn’s Disease (CD), is believed to be due to a dysregulation of the innate immune response. The complexity of the immune cascade offers both a challenge and an opportunity to researchers seeking out new treatments for IBD, as various points along the inflammatory pathways can be targeted for interruption. Sphinogosine-1-phosphate (S1P) is a phospholipid molecule with wide ranging biological effects caused by binding five known S1P receptor subtypes. Ozanimod is a small molecule drug that selectively targets S1P receptors 1 and 5 which play a crucial role in lymphocyte trafficking. In clinical trials for both UC and CD, it has been shown to induce a reversible lymphopenia which correlates with response to therapy. Reported adverse events include infection, anemia, and elevated liver enzymes. Rare instances of bradycardia, heart block, and macular edema were also reported. As a newly available therapy approved for UC patients, we aim to summarize ozanimod’s novel mechanism of action, pre-clinical and clinical trial results, and to give context to this newly available drug that gastroenterologists may utilize in their treatment algorithm.Keywords: S1P modulator, ozanimod, inflammatory bowel disease, ulcerative colitis, IBDhttps://www.dovepress.com/a-literature-review-of-ozanimod-therapy-in-inflammatory-bowel-disease--peer-reviewed-fulltext-article-TCRMs1p modulatorozanimodinflammatory bowel diseaseulcerative colitisibd |
| spellingShingle | Becher N Swaminath A Sultan K A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application Therapeutics and Clinical Risk Management s1p modulator ozanimod inflammatory bowel disease ulcerative colitis ibd |
| title | A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application |
| title_full | A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application |
| title_fullStr | A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application |
| title_full_unstemmed | A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application |
| title_short | A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application |
| title_sort | literature review of ozanimod therapy in inflammatory bowel disease from concept to practical application |
| topic | s1p modulator ozanimod inflammatory bowel disease ulcerative colitis ibd |
| url | https://www.dovepress.com/a-literature-review-of-ozanimod-therapy-in-inflammatory-bowel-disease--peer-reviewed-fulltext-article-TCRM |
| work_keys_str_mv | AT bechern aliteraturereviewofozanimodtherapyininflammatoryboweldiseasefromconcepttopracticalapplication AT swaminatha aliteraturereviewofozanimodtherapyininflammatoryboweldiseasefromconcepttopracticalapplication AT sultank aliteraturereviewofozanimodtherapyininflammatoryboweldiseasefromconcepttopracticalapplication AT bechern literaturereviewofozanimodtherapyininflammatoryboweldiseasefromconcepttopracticalapplication AT swaminatha literaturereviewofozanimodtherapyininflammatoryboweldiseasefromconcepttopracticalapplication AT sultank literaturereviewofozanimodtherapyininflammatoryboweldiseasefromconcepttopracticalapplication |